Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis

Tefferi, A; Pardanani, A; Gangat, N

Tefferi, A (通讯作者)，Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA.

HAEMATOLOGICA, 2023; 108 (11): 2919

Abstract

Janus kinase (JAK) 2 inhibitors are now part of the therapeutic armamentarium for primary and secondary myelofibrosis (MF). Patients with MF endure sh......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索